Indian Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market size stood at around USD XX Billion in 2019 and is projected to reach USD XX million by 2028, exhibiting a CAGR of XX% during the forecast period.
Paroxysmal nocturnal hemoglobinuria (PNH) is one of the rare blood disorders that can cause breakdown of red blood cells prematurely (hemolysis). Such condition may result when the body’s immune system is attacking the red blood cells and breaks them down due to lack of protein that protects them. The symptoms of this disorder include dark or bright red blood in urine, anemia, blood clotting in the veins, headaches, tiredness, shortness of breath, pale yellow skin. Paroxysmal Nocturnal Hemoglobinuria diagnosis is done on the basis of clinical evaluation, patient history, and several tests that are specialized specifically to identify Paroxysmal Nocturnal Hemoglobinuria cells likewise flow cytometry.
The rise in a number of blood and bone marrow related disorders and increase in geriatric population are the key factors which drive the market growth of PNH treatment market. In addition to this, the emergence of biologics and adoption of novel therapeutics are further pushing the market growth. Other factors include, emergence of biologics that target causal hemolytic defect or abnormal hematopoietic stem cell, rise in investment from government, public & private organizations for the development of novel drugs is acting as catalyst to market growth and high unmet demand for drugs in developing countries is also driving the market growth.
Market Restraining Factors
High cost of therapy and surgical procedures such as stem cell transplants (SCT), adverse side effects of available treatments, unfavorable reimbursement environment in developing regions and the risks associated with bone marrow transplant is hampering the market growth.